<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: $10,000 Health Challenge to Big Pharma</title>
	<atom:link href="http://avelient.com/BioPharmBlog/2008/06/24/10000-health-challenge-to-big-pharma/feed/" rel="self" type="application/rss+xml" />
	<link>http://avelient.com/BioPharmBlog/2008/06/24/10000-health-challenge-to-big-pharma/</link>
	<description>A blog on Biotech, the Pharmaceutical industry, and Personal Health</description>
	<pubDate>Fri, 21 Nov 2008 19:48:36 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6</generator>
		<item>
		<title>By: Avelient BioPharm Blog &#124; Little Exercise, Big Benefit</title>
		<link>http://avelient.com/BioPharmBlog/2008/06/24/10000-health-challenge-to-big-pharma/#comment-1506</link>
		<dc:creator>Avelient BioPharm Blog &#124; Little Exercise, Big Benefit</dc:creator>
		<pubDate>Tue, 12 Aug 2008 05:14:02 +0000</pubDate>
		<guid isPermaLink="false">http://avelient.com/BioPharmBlog/?p=105#comment-1506</guid>
		<description>[...] The process is activated through use of two drugs, AICR and GW1516, the former of which is currently licensed by Schering-Plough to help control bleeding in the human heart. It will probably be some time, however, before clinical trials of the two drugs in tandem can commence, and even longer before scientists understand the implications of changing how muscles function in the body. And I don&#8217;t know about you, but the thought of taking one or more pills for the rest of my life to maintain a svelte figure and a higher level of endurance isn&#8217;t appealing to me. Perhaps, if proven to be safe, whatever company decides to produce this drug can dangle it as a carrot to Mike Adams, sponsor of the $10,000 health challenge to big pharma. [...]</description>
		<content:encoded><![CDATA[<p>[...] The process is activated through use of two drugs, AICR and GW1516, the former of which is currently licensed by Schering-Plough to help control bleeding in the human heart. It will probably be some time, however, before clinical trials of the two drugs in tandem can commence, and even longer before scientists understand the implications of changing how muscles function in the body. And I don&#8217;t know about you, but the thought of taking one or more pills for the rest of my life to maintain a svelte figure and a higher level of endurance isn&#8217;t appealing to me. Perhaps, if proven to be safe, whatever company decides to produce this drug can dangle it as a carrot to Mike Adams, sponsor of the $10,000 health challenge to big pharma. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Avelient BioPharm Blog &#124; Pharmaceutical Start-ups: WellGen</title>
		<link>http://avelient.com/BioPharmBlog/2008/06/24/10000-health-challenge-to-big-pharma/#comment-1498</link>
		<dc:creator>Avelient BioPharm Blog &#124; Pharmaceutical Start-ups: WellGen</dc:creator>
		<pubDate>Tue, 29 Jul 2008 03:41:58 +0000</pubDate>
		<guid isPermaLink="false">http://avelient.com/BioPharmBlog/?p=105#comment-1498</guid>
		<description>[...] he&#8217;s the nutrition expert who issued a $10,000 challenge to BigPharma that I wrote about last week). For that matter, any health expert&#8217;s opinion might be interesting to hear. As a hopefully [...]</description>
		<content:encoded><![CDATA[<p>[...] he&#8217;s the nutrition expert who issued a $10,000 challenge to BigPharma that I wrote about last week). For that matter, any health expert&#8217;s opinion might be interesting to hear. As a hopefully [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
